HUDSON CAPITAL HUSN 深 沪
已收盘 05-26 16:00:00 美东时间
1.66
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.66
- 总市值 546.02万
- 52周最高 495000.0113
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 70000.00
- 委 比 0.00%
- 总股本 328.93万
- 历史最高 36355000.8263
- 量 比 0
- 振 幅 0.00%
- 历史最低 70000.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi gains EU approval recommendation for Scarlisa subcutaneous version
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding approval of a subcutaneous formulation of Sanofi's (SNY) Scarlisa (isatuximab) a...
03-27 22:56
Hudson Technologies Strikes Licensing Deal With Solstice Advanced Materials To Reclaim, Resale R-448A, R-449A Refrigerants
Hudson Technologies, Inc. (NASDAQ:HDSN) ("Hudson"; "the Company") a leading provider of innovative and sustainable refrigerant products and services to the Heating, Ventilation, Air Conditioning and Refrigeration
03-27 20:33
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Serina Therapeutics reported financial results for 2025, highlighting FDA clearance for SER-252, initiation of its Phase 1b trial, and a $30 million private placement financing. The company achieved operating expenses of $24.2 million, net loss of $19.4 million, and ended with $3.1 million in cash. Key milestones include advancing SER-252 for Parkinson's disease, securing new funding, and strengthening the balance sheet for upcoming clinical tria...
03-25 20:20
Serina Therapeutics to Present at the 38th Annual Roth Conference
Serina Therapeutics CEO Steve Ledger will discuss the company's proprietary POZ Platform technology and pipeline at the 38th Roth Conference. The company is advancing drug candidates for neurological diseases using its polymer-based delivery system, which enhances drug efficacy and safety. Serina also collaborates with Pfizer on lipid nanoparticle drug delivery. Key product SER-252 aims to provide continuous dopaminergic stimulation for Parkinson...
03-24 10:00
HMH Holding Inc. Announces Launch of Initial Public Offering
HMH Holding Inc. has launched an IPO of 10,520,000 Class A common shares, with an option for underwriters to purchase an additional 1,578,000 shares. The offering price is expected to range from $19.00 to $22.00 per share, with the shares to be listed on Nasdaq under the ticker "HMH." J.P. Morgan, Piper Sandler, and Evercore ISI are joint lead book-running managers, while Citigroup and DNB Carnegie are joint book-running managers. Stifel, Nordea,...
03-23 20:09
Erie Indemnity sets April 21, 2026 annual meeting date
Erie Indemnity sets April 21, 2026 annual meeting date Erie Indemnity’s board approved the record date of Feb. 20, 2026 for the annual meeting and related materials. The board set the annual meeting for April 21, 2026 and specified that only Class B common stockholders may vote. Directors accepted t
03-20 20:02
Sanofi SA Stock (SNY) Moved Up by 3.07% on Mar 19: Key Drivers Unveiled
• Sanofi's venglustat received FDA Breakthrough Therapy designation for Gaucher disease. • Dupixent gained FDA approval for allergic fungal rhinosinusitis. • Sanofi announced a €1 billion share buyback and opened a China innovation center.
03-19 19:15
UPDATE 1-Germany sets mid-April deadline for troubled fighter project with France
UPDATE 1-Germany sets mid-April deadline for troubled fighter project with France Adds Macron comments, background in paragraphs 6-9 BERLIN, March 19 (Reuters) - The German government has set a mid-April deadline for reaching an agreement with France on the crisis-hit FCAS fighter programme, a gove
03-19 18:21
WRAPUP 5-Central banks hawkish but cautious in war's shadow
WRAPUP 5-Central banks hawkish but cautious in war's shadow Adds SNB and Swedish Riksbank decisions in paragraph 12 US, Canada, Japan keep rates on hold amid inflation concerns Central banks warn risk of inflation if fuel costs remain high BOJ chief keeps alive expectation of near-term rate hike Bra
03-19 07:37
Boyd Group Q4 adjusted net earnings more than doubled to USD 22.77 million
Boyd Group Q4 adjusted net earnings more than doubled to USD 22.77 million Boyd Group published a fourth-quarter and full-year 2025 earnings release, reporting Q4 sales of USD 793.85 million, up 5.5%. Full-year sales rose 2.4% to USD 3.14 billion, as USD 94.2 million of incremental sales from 119 ne
03-18 18:01
